Insider buying last 90 days
No open-market insider purchases were filed for PTCT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PTCT insider filing, plotted on the chart in Gekko.Open PTCT in Gekko
NASDAQ: PTCT
PTC Therapeutics (PTCT) Stock Analysis & Forecast
Sep 28 close
$65.95+3.28 (+5.2%)
Gekko Brief
AI summaryThis week PTC Therapeutics completed its acquisition of ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics, with a rolling Biologics License Application for accelerated FDA approval planned for the fourth quarter of 2026. Cantor Fitzgerald raised its price target on the stock to $137.00 from $130.00 while maintaining an "overweight" rating, and separate commentary questioned the valuation of PTCT after a 175% run over three years. The company also disclosed inducement grants under Nasdaq Listing Rule 5635(c)(4).
PTCT closed at $65.95, up 5.2% on the day, though the shares remain below both the 50-day average of $70.66 and the 200-day average of $72.38, with the 50-day below the 200-day. The stock sits in the Accumulation zone of the GekkoIndex, with a reading of 63.4. Gekko Fair Value stands at $83.01, putting the current price 20.6% below that level.
The next earnings report is scheduled for 3 November 2026 after the close, 35 days out and beyond a typical 20-trading-day holding period. No insider, Congress or unusual options activity appears in the recent windows. Seasonality from this point in the calendar has averaged a 20-trading-day return of -2.8% over 5 years, rising in 2 of them, a pattern worth noting alongside the wide gap to consensus analyst targets.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
PTC Therapeutics price vs fair value
Close $65.95200-day averageGekko Fair Value $83.01
PTC Therapeutics quick facts
- Market cap
- $5.50B
- P/E ratio
- —
- Forward P/E
- 22.7
- EPS, TTM
- −$0.67
- Revenue, TTM
- $1.01B
- Profit margin
- -3.8%
- Dividend yield
- —
- Beta
- 0.55
- Volume
- 1.91M avg 1.21M
- 1-year return
- +14.0%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±8.8%
- 50-day average
- $70.66
- 200-day average
- $72.38
- Next earnings
- Nov 3 after close
- Shares outstanding
- 83.46M
PTC Therapeutics swing-trade checklist
PTC Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $65.95 is below the 50-day ($70.66) and 200-day ($72.38) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
63.4, Accumulation
Reading 63.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
20.6% below
Price is 20.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.8% on average
From this point in the calendar, the next 20 trading days averaged −2.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
PTC Therapeutics stock chart and price history
PTC Therapeutics closed at $65.95 on Sep 28, 2026, +14.0% over the past year, inside a 52-week range of $57.79 to $90.87.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.2%
- 3 months
- −19.1%
- 6 months
- −0.3%
- 1 year
- +14.0%
The full PTCT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PTCT in Gekko
Follow PTC Therapeutics through every session
Put PTCT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PTCT in GekkoFree for 7 days. No credit card required.
About PTC Therapeutics
PTC Therapeutics develops medicines for people with rare genetic disorders, working across early research, preclinical studies and clinical trials. The company is known for treatments aimed at Duchenne muscular dystrophy, including Translarna and Emflaza, which reach patients in the European Economic Area, the United States, and, in the case of Translarna, Brazil and Russia for a nonsense mutation form of the disease.
Beyond its Duchenne-focused products, the company sells Tegsedi and Waylivra for other rare conditions across Latin America and the Caribbean, and distributes Evrysdi in Brazil for spinal muscular atrophy in patients two months and older. It also uses a proprietary splicing platform to advance PTC518, a candidate being studied for Huntington's disease. Its work is supported by collaborations, including ones with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., the Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc., the last of which relates to commercializing Tegsedi and Waylivra in Latin America and the Caribbean.
PTC Therapeutics was established in 1998 and is headquartered in South Plainfield, New Jersey. Its shares are listed on the NASDAQ under the ticker PTCT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- ptcbio.com
PTC Therapeutics GekkoIndex: the smart money zone
PTC Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.4, in the Accumulation zone, down 6.1 points over five sessions.
63.4Accumulation
Down 6.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 30 | +2.9% | +6.9% | ||
| Accumulation (current zone) | 179 | +1.9% | +7.0% | ||
| Neutral | 412 | +0.6% | +2.4% | ||
| Distribution | 50 | −1.7% | −0.8% | ||
| Selling | 1 | Too few readings yet | |||
Average PTCT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PTCT price, zone by zone.Track PTCT in Gekko
Is PTC Therapeutics stock overvalued? Gekko Fair Value
PTC Therapeutics trades 20.6% below Gekko Fair Value of $83.01, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what PTC Therapeutics shares are worth, recalculated every trading day.
$83.01
Gekko Fair Value, Sep 26, 2026
20.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open PTCT in Gekko
PTC Therapeutics insider and Congress trading
No open-market insider purchases were filed for PTC Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PTCT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PTCT, plotted on the chart in Gekko.Open PTCT in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PTCT.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
PTC Therapeutics earnings: next date and track record
PTC Therapeutics reports on Nov 3, 2026, after the close (35 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 35 days away
- EPS estimate
- $0.29
- Revenue estimate
- $303.9M
7 of 8reports beat the EPS estimate
±6.3%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.92 est $0.24 | $360.5M est $298.6M | −8.7% |
| May 7, 2026 | −$0.03 est −$0.45 | $272.6M est $217.4M | +10.7% |
| Feb 19, 2026 | −$1.67 est −$0.21 | $164.7M est $279.5M | +2.5% |
| Nov 4, 2025 | $0.20 est −$1.19 | $211.0M est $281.5M | +5.7% |
| Aug 7, 2025 | −$0.83 est −$1.07 | $178.9M est $191.5M | −11.6% |
| May 6, 2025 | $10.04 est −$1.08 | $1.18B est $372.6M | +0.3% |
| Feb 27, 2025 | −$0.85 est −$1.12 | $213.2M est $232.4M | +8.4% |
| Nov 7, 2024 | −$1.39 est −$1.44 | $196.8M est $190.5M | +2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
PTC Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for PTC Therapeutics is $101.79, +54.3% from the last close, from 10 firms rating the stock in the last 90 days.
$101.79consensus 12-month target, +54.3% from the last close
Now $65.95Avg $101.79
Low $70High $137
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | Cantor Fitzgerald | $137 | +107.7% |
| Sep 14 | Leerink Partners | $98 | +48.6% |
| Sep 14 | Leerink Partners | $98 | +48.6% |
| Sep 2 | Wells Fargo | $109 | +65.3% |
| Aug 30 | TD Cowen | $90 | +36.5% |
+7.0%average 20-day move after past Accumulation readings
−2.8%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
PTC Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, PTC Therapeutics averaged −2.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 2 of 5 |
| Next 10 trading days | +1.6% | 4 of 5 |
| Next 15 trading days | +1.6% | 3 of 5 |
| Next 20 trading days | −2.8% | 2 of 5 |
| Next 30 trading days | +0.9% | 3 of 5 |
For scale, PTCT’s typical 20-trading-day move in either direction is about 8.8%.
PTC Therapeutics market cap and key statistics
PTC Therapeutics’s market cap is $5.50B and revenue of $1.01B over the last twelve months.
Valuation
- Market cap
- $5.50B
- Forward P/E
- 22.7
- EPS, TTM
- −$0.67
- Gekko Fair Value
- $83.01
Trading
- Volume
- 1.91M
- Avg volume, 20 days
- 1.21M
- 52-week high
- $90.87
- 52-week low
- $57.79
- Shares outstanding
- 83.46M
Financials
- Revenue, TTM
- $1.01B
- Profit margin
- -3.8%
- Return on equity
- -7740%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.55
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±8.8%
PTC Therapeutics stock news this week
Coverage of PTC Therapeutics this week reads positive: 4 positive, 1 neutral and 0 negative headlines.
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire, Sep 25
- PTC Therapeutics (PTCT) Stock Looks Expensive As Its 175% Run Draws FocusSimply Wall Street, Sep 25
- PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.comInvesting.com Australia, Sep 22
- PTC Therapeutics completes ST-920 gene therapy acquisitionInvesting.com, Sep 22
- Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00MarketBeat, Sep 22
- PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry DiseaseYahoo Finance, Sep 21
PTC Therapeutics peers
PTC Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
PTC Therapeutics stock FAQ
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $5.50B at the Sep 28, 2026 close of $65.95, with 83.46M shares outstanding.
What is the PTC Therapeutics stock forecast?
The consensus analyst 12-month price target for PTC Therapeutics is $101.79, +54.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is PTC Therapeutics stock overvalued or undervalued?
On Gekko’s estimate PTC Therapeutics is undervalued: the Sep 28, 2026 close of $65.95 is 20.6% below Gekko Fair Value of $83.01. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does PTC Therapeutics report earnings next?
PTC Therapeutics is expected to report on Nov 3, 2026, after the market closes (35 days away). Analysts expect earnings of $0.29 per share on revenue of $303.9M. PTC Therapeutics beat the earnings estimate in 7 of its last 8 reports, moving 6.3% on average across the report.
What is PTC Therapeutics’s 52-week high and low?
PTC Therapeutics’s 52-week high is $90.87 and its 52-week low is $57.79; it closed at $65.95 on Sep 28, 2026, +14.0% over the past year.
Is PTC Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See PTC Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.